The medical products maker announced plans to buy Sweden's Gambro for $4 bil, confirming rumors. Baxter (BAX) said Gambro's hospital-based dialysis gear will complement Baxter's home dialysis products and will help Baxter expand abroad. The news comes as analysts expect little organic growth from Baxter, with profit expected to rise in single digits for the next few years. Its biggest revenue generator, hemophilia, is likely to face new competition from Biogen Idec (BIIB) and Novo Nordisk (NVO). Baxter shares fell 0.9% to 65.22.